-
Selumetinib (INN), sold
under the
brand name Koselugo, is a
medication for the
treatment of children, two
years of age and older, with neurofibromatosis...
- was
approved for
medical use in the
United States in
February 2025.
Selumetinib, is a drug
produced by
Astra Zeneca sold
under the
brand name Koselugo...
-
symptoms or complications. However, in April, 2020, the FDA
approved selumetinib (brand name Koselugo) for the
treatment of
pediatric patients 2 years...
-
Roxadustat Salbutamol/budesonide
Savolitinib Saxagliptin Sebelipase alfa
Selumetinib Sodium zirconium cyclosilicate Tamoxifen Ticagrelor Tixagevimab/cilgavimab...
-
treatment of
advanced melanoma with a BRAF V600E or V600K mutation.
Selumetinib, had a
phase 2
clinical trial for non-small cell lung
cancer (NSCLC)...
-
Roxadustat Salbutamol/budesonide
Savolitinib Saxagliptin Sebelipase alfa
Selumetinib Sodium zirconium cyclosilicate Tamoxifen Ticagrelor Tixagevimab/cilgavimab...
-
Roxadustat Salbutamol/budesonide
Savolitinib Saxagliptin Sebelipase alfa
Selumetinib Sodium zirconium cyclosilicate Tamoxifen Ticagrelor Tixagevimab/cilgavimab...
-
Roxadustat Salbutamol/budesonide
Savolitinib Saxagliptin Sebelipase alfa
Selumetinib Sodium zirconium cyclosilicate Tamoxifen Ticagrelor Tixagevimab/cilgavimab...
-
inhibitor -
Approved 2022,
collaboration with
Mirati Therapeutics KOSELUGO (
Selumetinib) - MEK1/2
inhibitor -
Approved 2020,
licensed by
Astrazeneca VITRAKVI...
-
Roxadustat Salbutamol/budesonide
Savolitinib Saxagliptin Sebelipase alfa
Selumetinib Sodium zirconium cyclosilicate Tamoxifen Ticagrelor Tixagevimab/cilgavimab...
